CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

Bhatt, Shruti; Ashlock, Brittany M.; Natkunam, Yasodha; Sujoy, Victoria; Chapman, Jennifer R.; Ramos, Juan Carlos; Mesri, Enrique A.; Lossos, Izidore S.

doi:10.1182/blood-2013-01-481713

Cited by 77 publications

(45 citation statements)

References 32 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[50][51][52] In the current study, we were able to show that brentuximab-vedotin suppresses the growth of primary neoplastic MCs as well as proliferation of CD30 We next were interested in the molecular mechanism contributing to the antineoplastic actions of brentuximab-vedotin in MCs. In these experiments, we found that brentuximab-vedotin induces a G2/M cell cycle arrest as well as apoptosis in neoplastic MCs.…”

Section: Discussionmentioning

confidence: 79%

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Blatt¹,

Cerny-Reiterer

Schwaab

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• In a majority of patients with advanced SM, neoplastic MCs express the target receptor CD30.• The CD30-targeting drug brentuximab-vedotin blocks growth and survival in CD301 neoplastic MCs which favors drug development in advanced SM.The Ki-1 antigen (CD30) is an established therapeutic target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma. We have recently shown that CD30 is expressed abundantly in the cytoplasm of neoplastic mast cells (MCs) in patients with advanced systemic mastocytosis (SM). In the current study, we asked whether CD30 is expressed on the surface of neoplastic MCs in advanced SM, and whether this surface structure may serve as therapeutic target in SM. As assessed by flow cytometry, CD30 was found to be expressed on the surface of neoplastic MCs in 3 of 25 patients (12%) with indolent SM, 4 of 7 patients (57%) with aggressive SM, and 4 of 7 patients (57%) with MC leukemia. The immature RAS-transformed human MC line MCPV-1.1 also expressed cell surface CD30, whereas the KIT-transformed MC line HMC-

show abstract

Section: Discussionmentioning

confidence: 79%

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Blatt¹,

Cerny-Reiterer

Schwaab

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…8 Preclinical studies have suggested a potential role for brentuximab vedotin, the anti-CD30 monoclonal antibody. 9 The presence of EBV-induced cellular proliferation through the NF-B pathway also suggests the potential for treatment with agents that down-regulate this pathway, such as bortezomib. 10 Lenalidomide, an immunomodulatory agent, has also been used successfully.…”

Section: Therapymentioning

confidence: 99%

HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options

Krishnan¹,

Zaia

2014

Hematology

View full text Add to dashboard Cite

HIV infection is associated with an increased risk of malignancy, especially B-cell lymphoid malignancies. Many of these lymphomas are further driven by concomitant infection with viruses such as Epstein-Barr virus or Human Herpesvirus 8, the latter being implicated in uncommon types of lymphomas seen in the setting of HIV-1 infection. Treatment outcomes have improved due to infusional chemotherapy, high-dose chemotherapy, and effective antiretroviral therapy. Successful functional cure of HIV-1 infection has been demonstrated with the use of allogeneic hematopoietic stem cell transplantation. This result spurred a change in the field of HIV-1 management so that, ultimately, the goals of therapy would shift from not only curing the underlying lymphoma, but also curing the HIV-1 infection. Treatment options will be discussed with an emphasis on hematopoietic cell-based therapy for the underlying HIV infection.

show abstract

“…Brentuximab vedotin (SGN-35) is an antibody-drug conjugate in which a chimeric anti-CD30 antibody is combined with the synthetic microtubule-disrupting agent monomethylauristatin E (MMAE) (80). Since treatment with brentuximab vedotin also prolonged the survival of a PEL xenograft mouse model (81), brentuximab is expected to be a candidate for the treatment of PEL.…”

Section: Immunotherapymentioning

confidence: 99%